Cargando…

Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A

Background: Lansoprazole, amoxicillin, and clarithromycin are commonly used drugs for eradication of Helicobacter pylori (H. pylori). A few studies reported that the eradication rate was influenced by the functional polymorphism of CYP2C19, whose product metabolizes proton pomp inhibitors including...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Yoshiko, Goto, Yasuyuki, Kondo, Takaaki, Kurata, Mio, Nishio, Kazuko, Kawai, Sayo, Osafune, Tomo, Naito, Mariko, Hamajima, Nobuyuki
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1570618/
https://www.ncbi.nlm.nih.gov/pubmed/17003844
_version_ 1782130275072868352
author Ishida, Yoshiko
Goto, Yasuyuki
Kondo, Takaaki
Kurata, Mio
Nishio, Kazuko
Kawai, Sayo
Osafune, Tomo
Naito, Mariko
Hamajima, Nobuyuki
author_facet Ishida, Yoshiko
Goto, Yasuyuki
Kondo, Takaaki
Kurata, Mio
Nishio, Kazuko
Kawai, Sayo
Osafune, Tomo
Naito, Mariko
Hamajima, Nobuyuki
author_sort Ishida, Yoshiko
collection PubMed
description Background: Lansoprazole, amoxicillin, and clarithromycin are commonly used drugs for eradication of Helicobacter pylori (H. pylori). A few studies reported that the eradication rate was influenced by the functional polymorphism of CYP2C19, whose product metabolizes proton pomp inhibitors including lansoprazole. Methods: This study examined the eradication rate among 67 participants in the polymorphism study who visited Daiko Medical Center, Nagoya University from July 2004 to October 2005. The participants aged 20 to 69 years were classified into three group according to CYP2C19 genotype; rapid metabolizers (RM) with *1*1 genotype, intermediate metabolizers (IM) with *1*2 or *1*3 genotype, and poor metabolizers (PM) with *2*2, *2*3, or *3*3 genotype. For the genotype classification, G681A (681G for *1 and 681A for *2) and G636A (636G for *1 and 636A for *3) were genotyped by PCR with confronting two-pair primers (PCR-CTPP). They were also genotyped for IL-1B T-31C and TNF-A T-1031C by a duplex PCR-CTPP. Results: The eradication rate was 70.0% for RM, 93.9% for IM, and 85.7% for PM. The difference in the rate between RM and IM+PM was statistically significant (p=0.025). The eradication rate was highest for those with IL-1B -31CC; the p value was marginal among the whole subjects (χ(2)=3.78, p=0.05) and not significant among the RM group (χ(2)=1.60, p=0.21). The genotypes of TNF-A T-1031C had no associations with the eradication rate. But among the RM group, the odd ratio (OR) of the TNF-A CT for the eradication rate relative to TT was marginally reduced (OR=0.05, 95% confidence interval, 0.002-1.19). Conclusions: The present study confirmed the low eradication rate for RM. The reproduced finding provides evidence that the CYP2C19 genotype is useful to predict the success of the treatment. For the RM group, alternative regimens expected to be with a higher eradication rate will be recommended, especially to those with the TNF-A -1031C allele.
format Text
id pubmed-1570618
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-15706182006-09-25 Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A Ishida, Yoshiko Goto, Yasuyuki Kondo, Takaaki Kurata, Mio Nishio, Kazuko Kawai, Sayo Osafune, Tomo Naito, Mariko Hamajima, Nobuyuki Int J Med Sci Research Paper Background: Lansoprazole, amoxicillin, and clarithromycin are commonly used drugs for eradication of Helicobacter pylori (H. pylori). A few studies reported that the eradication rate was influenced by the functional polymorphism of CYP2C19, whose product metabolizes proton pomp inhibitors including lansoprazole. Methods: This study examined the eradication rate among 67 participants in the polymorphism study who visited Daiko Medical Center, Nagoya University from July 2004 to October 2005. The participants aged 20 to 69 years were classified into three group according to CYP2C19 genotype; rapid metabolizers (RM) with *1*1 genotype, intermediate metabolizers (IM) with *1*2 or *1*3 genotype, and poor metabolizers (PM) with *2*2, *2*3, or *3*3 genotype. For the genotype classification, G681A (681G for *1 and 681A for *2) and G636A (636G for *1 and 636A for *3) were genotyped by PCR with confronting two-pair primers (PCR-CTPP). They were also genotyped for IL-1B T-31C and TNF-A T-1031C by a duplex PCR-CTPP. Results: The eradication rate was 70.0% for RM, 93.9% for IM, and 85.7% for PM. The difference in the rate between RM and IM+PM was statistically significant (p=0.025). The eradication rate was highest for those with IL-1B -31CC; the p value was marginal among the whole subjects (χ(2)=3.78, p=0.05) and not significant among the RM group (χ(2)=1.60, p=0.21). The genotypes of TNF-A T-1031C had no associations with the eradication rate. But among the RM group, the odd ratio (OR) of the TNF-A CT for the eradication rate relative to TT was marginally reduced (OR=0.05, 95% confidence interval, 0.002-1.19). Conclusions: The present study confirmed the low eradication rate for RM. The reproduced finding provides evidence that the CYP2C19 genotype is useful to predict the success of the treatment. For the RM group, alternative regimens expected to be with a higher eradication rate will be recommended, especially to those with the TNF-A -1031C allele. Ivyspring International Publisher 2006-09-10 /pmc/articles/PMC1570618/ /pubmed/17003844 Text en © Ivyspring International Publisher. This is an open access article. Reproduction is permitted for personal and noncommerical use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Research Paper
Ishida, Yoshiko
Goto, Yasuyuki
Kondo, Takaaki
Kurata, Mio
Nishio, Kazuko
Kawai, Sayo
Osafune, Tomo
Naito, Mariko
Hamajima, Nobuyuki
Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
title Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
title_full Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
title_fullStr Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
title_full_unstemmed Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
title_short Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A
title_sort eradication rate of helicobacter pylori according to genotypes of cyp2c19, il-1b, and tnf-a
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1570618/
https://www.ncbi.nlm.nih.gov/pubmed/17003844
work_keys_str_mv AT ishidayoshiko eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT gotoyasuyuki eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT kondotakaaki eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT kuratamio eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT nishiokazuko eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT kawaisayo eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT osafunetomo eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT naitomariko eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa
AT hamajimanobuyuki eradicationrateofhelicobacterpyloriaccordingtogenotypesofcyp2c19il1bandtnfa